NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 200 filers reported holding NEKTAR THERAPEUTICS in Q2 2017. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $223,000 | -59.7% | 4,560 | -80.2% | 0.07% | -62.8% |
| Q3 2017 | $554,000 | -38.1% | 23,078 | -49.6% | 0.18% | -28.5% |
| Q2 2017 | $895,000 | +67.6% | 45,778 | +47.3% | 0.26% | +103.2% |
| Q3 2016 | $534,000 | -37.5% | 31,085 | -48.3% | 0.13% | -43.0% |
| Q2 2016 | $855,000 | +101.2% | 60,075 | +94.4% | 0.22% | +62.5% |
| Q1 2016 | $425,000 | – | 30,910 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |